Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial

1 Oct 1996

Abstract excerpt

Mutations of members of the ras family are among the most common oncogene mutations found in multiple myeloma (MM). We have examined the mutational status of the N- and K-ras genes at codons 12, 13, and 61 in 160 newly diagnosed MM patients enrolled on the Eastern Cooperative Oncology Group (ECOG) phase III clinical trial E9486. The total incidence of ras mutations was found to be 39% of the samples analyzed....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Multiple Myeloma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 8839865
DOI: 10.1182/blood.v88.7.2699.bloodjournal8872699

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III TrialPMID 8839865Read ↗

Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.Semantic proximity Read ↗

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.Semantic proximity Read ↗

p53 and RAS gene mutations in multiple myeloma.Semantic proximity Read ↗

Oncogenes in multiple myeloma: point mutation of N-ras.Semantic proximity Read ↗

RAS mutations - for better or for worse in multiple myeloma?Semantic proximity Read ↗

RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.Semantic proximity Read ↗

Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.Semantic proximity Read ↗

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple MyelomaSemantic proximity Read ↗

The oncoprotein phenotype of plasma cells from patients with multiple myeloma.Semantic proximity Read ↗

Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.Semantic proximity Read ↗

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.Semantic proximity Read ↗

Clinical and biological significance of RAS mutations in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.